drugset / Trial / NCT01615354

A Study of Aleglitazar in Combination With Oral Contraceptive Healthy Volunteers

NCT01615354

Phase 1 Completed 18 enrolled Hoffmann-La Roche
RandomizedCrossoverDouble-blind

Summary

This randomized, double-blind, placebo-controlled, cross-over study will assess the effect of aleglitazar on the pharmacokinetics and pharmacodynamics on Microgynon® in healthy volunteers. Volunteers will receive multiple oral doses of aleglitazar in one period; in the other period volunteers will receive placebo.

Timeline

Start
2012-07
Primary completion
2013-01
Completion
2013-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Microgynon Unknown Oral
Subject aleglitazar Small molecule Oral

Indications

No indication recorded.